Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4940591 | 0.83 | FFAR3 (0.31) | LDHASRRFFAR3 | |
| SCHEMBL2710907 | 0.79 | LDHA (0.38) | LDHASRRFFAR3TSHRMGAM | |
| SCHEMBL2967817 | 0.77 | LDHA (0.36) | LDHASRRFFAR3TSHRMGAM | |
| SCHEMBL7642543 | 0.77 | LDHA (0.36) | LDHASRRTSHRGAA | |
| SCHEMBL620518 | 0.76 | LDHA (0.35) | LDHASRRFFAR3TSHRMGAM | |
| SCHEMBL3929483 | 0.76 | CYP2D6 (0.35) | LDHASRRFFAR3TSHRMGAM | |
| SCHEMBL9820094 | 0.76 | LDHA (0.35) | LDHASRRFFAR3TSHRMGAM | |
| SCHEMBL9065496 | 0.75 | LDHA (0.31) | LDHASRR | |
| SCHEMBL10770038 | 0.74 | LDHA (0.33) | LDHASRRFFAR3TSHRMGAM | |
| SCHEMBL10550164 | 0.74 | LDHA (0.33) | LDHASRRFFAR3TSHRMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | PDE4A, PDE4B, PDE3B | LDHA 3863/4885SRR 234/4885FFAR3 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.